Refining prognosis in pancreatic cancer 🎯 Accurate staging is vital for improving outcomes in pancreatic adenocarcinoma. A study comparing the 7th and 8th editions of the AJCC TNM staging system in 214 surgically treated patients reveals key findings. pubmed.ncbi.nlm.nih....

Did you know? By combining omics, mathematical models, synthetic biology, AI & microfluidics, we can... 🔎 Identify novel therapeutic targets 💡 Predict which nanobodies will bind best to their targets 🙌 Validate the efficacy of the nanobodies aladdin-project.eu/a...

ALADDIN at the XXI National Meeting of Sociedad Española de Biología Celular 🙌 Last week, PI Javier Martinez-Useros from the Instituto Investigación Sanitaria Fundación Jiménez Díaz joined the event and presented the ALADDIN project. #ALADDINproject #EICPathfinder

50 years on: monoclonal antibodies evolved from lab reagents to lifesaving drugs for millions. 🎉 This article by Chan et al. (Genentech) explores the journey and future of monoclonal antibodies, from bispecifics to AI-powered design. Read more:

Stay up to date on the latest ALADDIN news! 📰 Our blog is the go-to for relevant updates about the project. Discover our meeting summaries, interviews with project partners, and more: aladdin-project.eu/n...

Pancreatic cancer is deadly & early detection is difficult. Blood-circulating miRNAs show promise as minimally invasive biomarkers for early diagnosis, as shown in this review by Powrózek et al.🩸 Discover the latest findings:

Collaboration fueling innovation 🤝🔬 At ALADDIN, partners across Europe are working together to accelerate nanobody discovery and validate their effectiveness against pancreatic and colorectal cancers. 🔗: aladdin-project.eu/c...

Last month, the ALADDIN team at @inlnano.bsky.social presented the project during an Early-Stage Researcher career fair. 🧬 During the event, which also attracted visitors from R&I-based companies, Alejandro Rodriguez & Mohammad Kiani presented the microfluidics devices developed in ALADDIN. 🔬

50 years on: monoclonal antibodies evolved from lab reagents to lifesaving drugs for millions. 🎉 This article by Chan et al. (Genentech) explores the journey and future of monoclonal antibodies, from bispecifics to AI-powered design. Read more:

Recap of our second annual meeting 🔔 Last month, the ALADDIN consortium came together in Linköping, Sweden, to exchange news on project progress and future plans. Read the summary of the meeting in our blog: aladdin-project.eu/aladdin-seco...

Nanobodies are transforming modern medicine, but the path to discovery is long and costly. ALADDIN accelerates nanobody discovery by integrating many technologies into one platform—from biological processes to AI, mathematical modelling & microfluidics tools💡 aladdin-project.eu/a...

ALADDIN was represented at the Single Antidomain Antibodies Conference 2025 in Utrecht. 🇳🇱 Project researchers Lidia Cerdán & Yago Margolles presented posters & the ALADDIN coordinator, Luis Ángel Fernández, gave a presentation at the three-day event. #ALADDINproject #singledomainantibodies

50 years ago, a simple idea changed medicine forever 🧬 Discover how the invention of monoclonal antibodies revolutionised science and health care, and why free exchange of ideas was key to this breakthrough. 🔗 Read the story:

Replicating the human immune system to speed up therapeutic antibody discovery 🔬 ALADDIN develops a platform that brings various technologies together to rethink nanobody discovery. In the long run, it can contribute to faster, more efficient drug development! aladdin-project.eu/

Zebrafish at the forefront of cancer research 🐠 In ALADDIN, cancer tumours are transplanted into zebrafish embryos to study nanobody performance. In our blog, Lasse Jensen from @liu.se explains why zebrafish are used in ALADDIN & his team’s role in the project. aladdin-project.eu/l...

Can nanobodies be used to treat brain disorders? There’s promise, as shown by a study by Mathieu Oosterlaken et al. published in @nature.com. Researchers developed a bivalent nanobody that improved cognitive deficits in mice with NMDA receptor hypofunction. 🐁🧠

Nanobodies: tiny but powerful fragments of antibodies first discovered in camelids. 🐪 In ALADDIN, we’re developing a platform to enhance their discovery and engineering—supported by molecular biology, AI, mathematical modelling, and microfluidics. 🧬 aladdin-project.eu/

Second annual meeting: completed 🚀 Earlier this month, the ALADDIN consortium came together in Sweden to discuss project progress and upcoming tasks. Take a look at our blog for a recap of the meeting: aladdin-project.eu/aladdin-seco...

Nanobodies targeting lung cancer 🫁 Researchers at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) have developed a nanobody-based technology that identifies and attacks lung cancer cells, opening up new possibilities for cancer therapy.

The second annual ALADDIN project meeting has come to an end! 👏 We thank our hosts from @liu.se for a well-organised meeting and our project partners for their presentations & insightful conversations. As we approach our halfway milestone, things will only speed up! #EICPathfinder

The first day of the ALADDIN project meeting ended with a tour of the @liu.se zebrafish facility and PI Lasse Jensen's lab. 🐠 The second day of the meeting is now in full swing, focusing on the project support system: 🔹 Communication & dissemination 🔹 Exploitation 🔹 Coordination #EICPathfinder

Day 1 of our meeting is drawing to a close 🔎 We've discussed... 🔸 Biological & AI technologies for nanobody (Nb) discovery & optimisation 🔸 Developing a microfluidic cell sorting device to discover Nbs 🔸 Technologies to assess Nb candidates 🔸 Identifying targets in pancreatic & colorectal cancers

Our second annual meeting has begun! 📢 Our consortium has gathered at @liu.se to discuss project progress & future tasks. 🧬 Our project coordinator, Luis Ángel Fernández from @cnb-csic.bsky.social, welcomed all partners & explained the agenda of the upcoming two days. #EICPathfinder

One day left for our annual project meeting! The ALADDIN project partners are arriving in Linköping, Sweden 🇸🇪, tomorrow to kick off our second in-person meeting. Keep an eye on our social media accounts for updates! 🙌 @liu.se, thank you for having us! #EICPathfinder

In our blog, Lasse Jensen, Senior Associate Professor at @liu.se & founder of BioReperia, explains: 💡 His team’s role in ALADDIN 🐠 Why zebrafish are used to test nanobody efficacy 💎 How the developed zebrafish models can be used beyond the project aladdin-project.eu/l...

Nasal antibody spray protects mice from allergies & asthma 🐁 In a study published in Frontiers Immunology, researchers administered intranasal allergen-specific monoclonal antibodies in mice, shielding them against mugwort pollen-induced rhinitis & asthma.

The ALADDIN team gathers in Sweden in September! 🇸🇪 Our partners will come together in Linköping at the beginning of the month for the annual ALADDIN project meeting. Stay tuned for updates! Discover more: aladdin-project.eu/s...

New blog alert! 📣 We interviewed Lasse Jensen from @liu.se about his team’s role in the ALADDIN project. They transplant tumours from cancer patients into zebrafish embryos to study the effectiveness of nanobodies against them 🔬 Read more: aladdin-project.eu/l...

The annual ALADDIN meeting takes place next month! Our consortium will gather in Linköping, Sweden, on 3–4 September 🇸🇪 We look forward to discussing key advancements & future steps among our international team! Read more: aladdin-project.eu/second-aladd...

Nanobody to fight Nipah and Hendra viruses 🦠 Researchers from The University of Queensland have found a nanobody to neutralise the Nipah (NiV) & Hendra (HeV) viruses, which haven’t previously had approved human vaccines or therapies. Discover the study: www.nature.com/artic...

Analysing nanobody efficiency in zebrafish 🐠 Zebrafish & humans share up to 80% of the same disease-causing genes, making the fish suitable for testing treatment effectiveness. In ALADDIN, the team at @liu.se, led by Lasse Jensen, does just that. 🔗: aladdin-project.eu/l...

Changing the world, one innovation at a time 🔬 In ALADDIN, researchers collaborate to enhance #nanobody discovery. This could improve the drug discovery process & treating diseases like cancer! Funded by the European Innovation Council’s #EICPathfinder Open. 💪 aladdin-project.eu/#nanobody

Nanobodies hold great potential for cancer treatment. But their discovery is slow, expensive, and requires advanced skills & equipment. ALADDIN streamlines the process by combining nanobody development & identification technologies into one platform 🤝 aladdin-project.eu

The Single Domain Antibodies Conference comes again! This year, the conference will be held in Utrecht, the Netherlands, from 29 September to 1 October 2025 🇳🇱 Registration is open until 22 September! Discover more: www.uu.nl/en/researc...

In ALADDIN, we develop a platform to make #nanobody discovery… 🏃 Faster 💰 Less expensive 🔨 Less laborious 💻 More automated Our approach could significantly improve the process! Find out more: aladdin-project.eu/#nanobody

Our partners in the spotlight: Meet Lasse Jensen from @liu.se! 📣 In ALADDIN, Jensen’s team transplants tumours from cancer patients into zebrafish embryos to study the effectiveness of nanobodies against them. Read more on the ALADDIN blog: aladdin-project.eu/l...

Rapid visualisation of thick tissue samples using nanobodies 🔍 Researchers from Juntendo University have developed an improved 3D immunohistochemistry (3D-IHC) technique based on nanobodies. Discover the article in Communications Biology: phys.org/news/2025-0...

ALADDIN gathers institutions across sectors: 🔬 Research centres: @cnb-csic.bsky.social @inl.int @isciiisalud.bsky.social Instituto de Investigación Sanitaria Fundación Jiménez Díaz 🏫 Universities: @liu.se @hebrewuniversity.bsky.social 💼 SMEs: InCellia & ZirkaInnotech aladdin-project.eu/c...

Zebrafish play a key role in ALADDIN—but why? 🐠 For our latest blog article, we interviewed Lasse Jensen, Senior Associate Professor at @liu.se, about his team’s role & the importance of zebrafish for the success of ALADDIN. Discover the interview: aladdin-project.eu/l...

Nanobody funding news! 🔬 We’re happy to see the EIC fund TargED Biopharmaceuticals, a company developing a nanobody therapy for thrombosis, in the latest #EICAccelerator call. We are glad that @ec.europa.eu supports innovations in #nanobody discovery! targedbiopharmaceuti...

A nanobody to target Herpes simplex 🦠 In an article published in @natcomms.nature.com, authors Jing Hu (University Of Science And Technology Of China) et al. describe Nb14-32-Fc, a bispecific nanobody dimer, serving as a candidate to treat the Herpes simplex virus. www.nature.com/artic...

Discover our approach! ✓ 🔎 Identify therapeutic targets from #cancer samples 🦠 Replicate how the immune system generates antibodies against antigens ⬆️ Improve antibodies’ binding to their targets ✅ Validate that the antibodies work against the tumour targets aladdin-project.eu/a...

Discussing past & future activities! 💡 The ALADDIN team had an online meeting this week. Our partners shared updates from the previous months & plans for upcoming work 📆 It was great seeing colleagues, even through the screen, and we're excited about our next in-person meeting in September!

Unveiling the advances in nanobody engineering ⚙️ In this article published in the Journal of Nanobiotechnology, authors Jiwei Liu et al. review the latest progress in the field of nanobody engineering. Find out more: jnanobiotechnology.b...

New nanobody to protect mice against influenza 🚀 Researchers at the University of Gothenburg, Lanzhou University & the Harbin Veterinary Research Institute discovered a molecule protecting mice from influenza. It can help develop treatments & influenza vaccines 💉 www.nature.com/artic...

Nanobodies against mpox 🦠 This study, published in Cell Discovery by Xuehua Yang et al., describes the identification of a nanobody from a synthetic nanobody library to effectively neutralise mpox. Read the article: www.nature.com/artic...

From patient data to preclinical validation 🔍 ALADDIN integrates many technologies into one platform to improve therapeutic antibody discovery. Our platform mimics the immune system to identify, optimise & validate nanobody candidates quickly & precisely. ⏰ aladdin-project.eu/

Discover the latest article by ALADDIN researchers! 📣 Lídia Cerdán et al. describe developing nanobodies to neutralise variants of SARS-CoV-2 by combining immune library probing with structure-based computational design 🖥️ www.tandfonline.com/doi/full/10.... @cnb-csic.bsky.social @ulpgc.es

🔬 From smart target identification to advanced nanobody validation, we at ALADDIN are redefining the discovery of therapeutic antibodies. Learn more about our groundbreaking platform and the technologies driving the next generation of cancer therapies! Explore here 🔗: aladdin-project.eu/

If you are into... 🎧 podcasts 🔬 updates in the field of antibodies ...the Antibody News podcast by the Antibody Society is the perfect media for you! Enjoy the listening: www.antibodysociety....